Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

6Total
P 1 (5)
P 2 (1)

Trial Status

Unknown4
Active Not Recruiting2
Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT04003649Phase 1Active Not Recruiting

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

NCT06404034Unknown

Expanded Access to Gallium Maltolate (GaM)

NCT07193628Phase 1RecruitingPrimary

B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma

NCT02208362Phase 1Active Not Recruiting

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

NCT04385173Phase 1Unknown

Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma

NCT04077866Phase 1Unknown

B7-H3 CAR-T for Recurrent or Refractory Glioblastoma

NCT04674527Phase 2UnknownPrimary

Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma

Showing all 7 trials

Research Network

Activity Timeline